Publications

 

  1. De Pretis, F.; Osimani, B. New Insights in Computational Methods for Pharmacovigilance: E-Synthesis, a Bayesian Framework for Causal Assessment. Int. J. Environ. Res. Public Health 2019, 16(12), 2221; https://doi.org/10.3390/ijerph16122221
  2. Beebe C., Poellinger R. Bayesian Confirmation by Analogy. – under review. Preprint
  3.  Poellinger, R. (2018) Analogy-Based Inference Patterns in Pharmacological Research. Forthcoming in: Osimani, Barbara & Adam La Caze (eds.): Uncertainty in Pharmacology: Epistemology, Methods, and Decisions. Boston Studies in Philosophy of Science. Springer, 2018. Preprint
  4. Landes, Jürgen, Barbara Osimani, Roland Poellinger: Epistemology of Causal Inference in Pharmacology. Towards a Framework for the Assessment of Harms. European Journal for Philosophy of Science, Volume 8, Issue 1, pages 3-49, 2018. Doi: 10.1007/s13194-017-0169-1.
  5. Osimani B. (2018) What’s Hot in Mathematical Philosophy: Formal Epistemology of Medicine. The Reasoner, vol. 12 (2): 15-16. Open Access https://blogs.kent.ac.uk/thereasoner/files/2018/01/TheReasoner-122.pdf
  6. Jürgen Landes. What’s Hot in Mathematical Philosophy: Pirate Games. The Reasoner, 12 (5): pages 41–42, 2018. Open Access.
    https://blogs.kent.ac.uk/thereasoner/files/2018/05/TheReasoner-125.pdf.
  7. Landes J. Osimani B. Poellinger R. “E-Synthesis: a Bayesian Framework for Causal Assessment from Heterogeneous Evidence” – under review. Preprint
  8. Landes, J. Osimani B. Varieties of Error and Varieties of Evidence in Scientific Inference. – under review. Preprint
  9.  Jürgen Landes, Christian Wallmann and Jon Williamson. The Principal Principle, admissibility, and normal informal standards of what is reasonable. – under review.
  10. Jürgen Landes. Formal Epistemology meets Mechanism Design. – under review. Preprint
  11.  Jürgen Landes. Varied Evidence and the Elimination of Hypotheses. – under review. Preprint
  12. Jürgen Landes. Variety of Evidence. Erkenntnis, 41 pages. Doi: 10.1007/s10670-018-0024-6. Preprint
  13. Landes J. Osimani B. Less is More: On the Value of Agents’ Testimony. – under review. Preprint
  14. Jürgen Landes, Christian Wallmann and Jon Williamson. The Principal Principle, admissibility, and normal informal standards of what is reasonable. Preprint
  15. Alessandro Demichelis (2018). An epistemic approach to vaccine hesitancy. Master’s Thesis, University of Florence. Preprint
  16. Osimani B. (2018) Social Games and Epistemic Losses: Reliability and higher order evidence in medicine and Pharmacology. In: Osimani B., La Caze A. (eds.) Uncertainty in Pharmacology: Epistemology, Methods and Decisions”. Springer: Boston Series in Philosophy of Science. Preprint
  17. Osimani B. (2018) The Meaning of Meta-Analyses. In: Osimani B., La Caze A. (eds.) (2018) Uncertainty in Pharmacology: Epistemology, Methods and Decisions”. Springer: Boston Series in Philosophy of Science.
  18. Jürgen Landes. L&P-updating – All Bets Are Off. The Reasoner, 12 (2): page 10, 2018. Open Access https://blogs.kent.ac.uk/thereasoner/files/2018/01/TheReasoner-122.pdf
  19. Jürgen Landes (2018) An Evidence-Hierarchical Decision Aid for Ranking in Evidence-Based Medicine. In Barbara Osimani and Adam La Caze, editors, Uncertainty in Pharmacology: Epistemology, Methods and Decisions, Boston Studies for the Philosophy and History of Science. Springer. Preprint
  20. Osimani, Barbara and Roland Poellinger: Causal Inference from Computer Simulation: A Protocol for Model Validation. In: Carusi, Annamaria, Blanca Rodriguez, Kevin Burrage (eds.): Validation and Models in Computational Biomedical Science. Progress in Biophysics and Molecular Biology, 2016 (forthcoming)
  21. Samuel Fletcher, Jürgen Landes, and Roland Poellinger (eds.): Special Issue on “Evidence Amalgamation in the Sciences”, Synthese, 2019.
  22. Samuel Fletcher, Jürgen Landes, and Roland Poellinger: Evidence Amalgamation in the Sciences: an introduction, 26 pages, substantial editorial, 2019.
    Doi: 10.1007/s11229-018-1840-6
  23.  Mebius A. (2017) Assigning Functions to Medical Technologies. Philosophy & Technology, Volume 30, pages 321–331. Doi: 10.1007/s13347-016-0241-3
    Open Access: Paper
  24. Alessandro Demichelis: Drug Safety, Probabilistic Causal Assessment, and Evidence Synthesis, 27–28 January. The Reasoner, Volume 11, Number 3 – March 2017, pages 10-11. https://blogs.kent.ac.uk/thereasoner/files/2015/01/TheReasoner-113.pdf
  25. James Hawthorne, Jürgen Landes, Christian Wallmann and Jon Williamson. The Principal Principle implies the Principle of Indifference. British Journal for the Philosophy of Science, 68: pages 123–131, 2017. Doi: 10.1093/bjps/axv030. Preprint
  26. Landes J., Williamson J. Objective Bayesian nets from consistent datasets. In Proceedings of MaxEnt 2015. AIP, 2016. pages 020007-1 – 020007-8. Open Access. Doi: 10.1063/1.4959048 Preprint
  27. Jürgen Landes and George Masterton. Invariant Equivocation. Erkenntnis, 82: pages 141–167, 2017. SecondOrder. Doi: 10.1007/s10670-016-9810-1.
  28. Jürgen Landes and Jon Williamson (2016): the Journal of Applied Logic published a special issue. Editorial Preprint
  29.  J Howick, A Mebius. (2015) Randomized trials and observational studies: the current philosophical controversy. Handbook of the Philosophy of Medicine. Springer. Preprint
  30. Osimani B. (2016) Interview with Glenn Shafer. The Reasoner 10 (6): 44-47.
  31. Osimani B., Mignini F. (2015) Causal Assessment of Pharmaceutical Treatments: Why Standards of Evidence Should not be the Same for Benefits and Harms. Drug Safety, 38 (19): 1-11.
  32. Osimani B. and Russo F. (2015) Bayesianisme objectif et principe de précaution. In Drouet I. (eds), Le bayésianisme auourd’hui. Fondements et pratiques. Matériologiques.
  33. Osimani B. (2014) Safety vs. efficacy assessment of pharmaceuticals: Epistemological rationales and methods. Preventive Medicine Reports, (1): 9-13. http://www.sciencedirect.com/science/article/pii/S2211335514000047
  34. Osimani B. (2014) Causing something to be one way rather than another: Genetic information, causal specificity and the relevance of linear order. Kybernetes, Special Issue on Information: Space, Time, and Identity (DTMD 2013); 43 (6): 865-81.
  35. Osimani B. (2013) Hunting side effects and explaining them: should we reverse evidence hierarchies upside down? Topoi (Special Issue: Evidence and Causality in the Sciences) October
  36. Osimani B. (2013) Until RCT-proven? On the asymmetry of evidence requirements for risk assessment. Journal of Evaluation in Clinical Practice, 19: 454–46.
  37. Osimani B. (2013) The precautionary principle in the pharmaceutical domain: a philosophical enquiry into probabilistic reasoning and risk aversion. Health, Risk and Society, 15 (2): 123-143.
  38. Osimani B. (2013) An epistemic analysis of the precautionary principle. Dilemata: International Journal of Applied Ethics, 11: 149-167.
  39. Osimani B. (2012) Il contributo delle teorie filosofiche della causalità al dibattito sull’informazione genetica. MEDIC, Special issue: Genetic Information. Epistemological, Anthropological and Ethical Issues, 20 (2): 19-46.
  40. Osimani, B. (2012). Genetic Information. Epistemological, Anthropological and Ethical Issues. Editorial. MEDIC, Methodology and Innovation for Clinical Innovation (editorial), 20 (2): 10-18.
  41. Osimani B. (2012) Risk Information Processing and Rational Ignoring in the Health Context. Journal of Socio-Economics 41: 169-179. DOI information: 10.1016/j.socec.2011.10.009
  42. Osimani B. (2011) Per una formalizzazione bayesiana del principio di precauzione. In: E. Pariotti, G. Guerra, M. Piccinni, D. Ruggiu. “Regolamentazione, forme di responsabilità e nanotecnologie” Dipartimento di Diritto comparato dell’Università di Padova – CIGA, Il Mulino.
  43. Osimani B., F. Russo, J. Williamson (2011) Scientific evidence and the law: an objective Bayesian formalisation of the precautionary principle in pharmaceutical regulation, Journal of Philosophy, Science and Law (11).
  44. Osimani B. (2011) Is the precautionary principle risk aversive? An enquiry in the domain of pharmaceutical decisions. Studia Universitatis Babes-Bolyai – Bioethica, LVI, 2: 57-70.
  45. Osimani B. (2010) Pharmaceutical risk communication: sources of uncertainty and legal tools of uncertainty management. Health Risk and Society, October, Volume 12 Issue 5: 453-469.
  46. Osimani B. (2009) Modus tollens probabilized: deductive and inductive methods in medical diagnosis. MEDIC, Methodology and Education for Clinical Innovation, vol. 17 (1-2): 43-59.
  47. Osimani B. (2007) “The epistemic nature of package leaflet information: A contribution to the legal debate on the role of package leaflets in therapeutic consent”. MEDIC Special Issue: Dicember 2007/ April 2008: 72-90.
  48. Osimani B. (2007) Probabilistic information and decision making in the health context : The package leaflet as basis for informed consent. Doctoral Thesis: Università della Svizzera italiana, 2007; 2007COM009 oai:doc.rero.ch:20120314100721-NN urn:nbn:ch:rero-006-110691. http://doc.rero.ch/record/28759?ln=fr

 

Advertisements